Dogwood Therapeutics, Financials
| DWTX Stock | 2.60 0.05 1.89% |
Investors should never underestimate Dogwood Therapeutics,'s ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Dogwood Therapeutics,'s cash flow, debt, and profitability to make informed and accurate decisions about investing in Dogwood Therapeutics,.
Net Income |
|
Dogwood | Select Account or Indicator |
Understanding current and past Dogwood Therapeutics, Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Dogwood Therapeutics,'s financial statements are interrelated, with each one affecting the others. For example, an increase in Dogwood Therapeutics,'s assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Dogwood Therapeutics,'s accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Dogwood Therapeutics,. Check Dogwood Therapeutics,'s Beneish M Score to see the likelihood of Dogwood Therapeutics,'s management manipulating its earnings.
Dogwood Therapeutics, Stock Summary
Dogwood Therapeutics, competes with Viracta Therapeutics, Viking Therapeutics, Dyadic International, and Vanda Pharmaceuticals. Dogwood Therapeutics, is entity of United States. It is traded as Stock on NASDAQ exchange.Specialization | Healthcare, Biotechnology |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| CUSIP | 92829J104 |
| Older Symbol | VIRI |
| Location | Georgia; U.S.A |
| Business Address | 44 Milton Avenue, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.dwtx.com |
| Phone | 866 620 8655 |
Dogwood Therapeutics, Key Financial Ratios
| Net Income | (5.3 M) | ||||
| Total Asset | 4.17 M | ||||
| Retained Earnings | (61.47 M) |
Dogwood Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Dogwood Therapeutics,'s current stock value. Our valuation model uses many indicators to compare Dogwood Therapeutics, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Dogwood Therapeutics, competition to find correlations between indicators driving Dogwood Therapeutics,'s intrinsic value. More Info.Dogwood Therapeutics, is rated below average in net income category among its peers. It is rated below average in total debt category among its peers . Dogwood Therapeutics, reported Net Loss of (5.3 Million) in 2023. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Dogwood Therapeutics,'s earnings, one of the primary drivers of an investment's value.Dogwood Therapeutics, Systematic Risk
Dogwood Therapeutics,'s systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Dogwood Therapeutics, volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Dogwood Therapeutics, correlated with the market. If Beta is less than 0 Dogwood Therapeutics, generally moves in the opposite direction as compared to the market. If Dogwood Therapeutics, Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Dogwood Therapeutics, is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Dogwood Therapeutics, is generally in the same direction as the market. If Beta > 1 Dogwood Therapeutics, moves generally in the same direction as, but more than the movement of the benchmark.
Dogwood Therapeutics, Thematic Clasifications
Dogwood Therapeutics, is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
| Pharmaceutical Products | View |
Dogwood Therapeutics, November 29, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Dogwood Therapeutics, help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Dogwood Therapeutics,. We use our internally-developed statistical techniques to arrive at the intrinsic value of Dogwood Therapeutics, based on widely used predictive technical indicators. In general, we focus on analyzing Dogwood Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Dogwood Therapeutics,'s daily price indicators and compare them against related drivers.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 69.76 | |||
| Value At Risk | (18.49) | |||
| Potential Upside | 15.01 |
Additional Tools for Dogwood Stock Analysis
When running Dogwood Therapeutics,'s price analysis, check to measure Dogwood Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dogwood Therapeutics, is operating at the current time. Most of Dogwood Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Dogwood Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dogwood Therapeutics,'s price. Additionally, you may evaluate how the addition of Dogwood Therapeutics, to your portfolios can decrease your overall portfolio volatility.